The Systemic Synuclein Sampling Study: Toward a biomarker for Parkinson's disease

Biomarkers in Medicine

Volumn 11, Issue 4, 2017, Pages 359-368

  Visanji, Naomi P ^a   Mollenhauer, Brit ^b   Beach, Thomas G ^c   Adler, Charles H ^d   Coffey, Christopher S ^e   Kopil, Catherine M ^f   Dave, Kuldip D ^f   Foroud, Tatiana ^g   Chahine, Lana ^h   Jennings, Danna ⁱ  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b PARACELSUS ELENA KLINIK   (Germany)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^g INDIANA UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

Biofluid; Biomarker; Parkinson's disease; Tissue; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE TRANSPORTER;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; COLON BIOPSY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DOPAMINERGIC ACTIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RELIABILITY; SALIVA LEVEL; SALIVARY GLAND BIOPSY; SKIN BIOPSY; SUBMANDIBULAR GLAND; AGED; BLOOD; CASE CONTROL STUDY; CEREBROSPINAL FLUID; COLON; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SKIN;

AGED; ALPHA-SYNUCLEIN; BIOMARKERS; CASE-CONTROL STUDIES; COLON; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MIDDLE AGED; PARKINSON DISEASE; SKIN; SUBMANDIBULAR GLAND; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85016812835     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm-2016-0366     Document Type: Article

References (66)

1. Schulz-Schaeffer WJ. The synaptic pathology of-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120(2), 131-143 (2010).
2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95(11), 6469-6473 (1998)
3. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study. Neurology 83(5), 406-412 (2014).
4. Simonsen AH, Kuiperij B, El-Agnaf OM, et al. The utility of-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomarkers Med. 10(1), 19-34 (2016)
5. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119(6), 689-702 (2010)
6. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alphasynuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's diseaserelated brain pathology. Neurosci. Lett. 396(1), 67-72 (2006).
7. Visanji NP, Marras C, Hazrati LN, Liu LW, Lang AE. Alimentary, my dear Watson The challenges of enteric alphasynuclein as a Parkinson's disease biomarker. Mov. Disord. 29(4), 444-450 (2014).
8. Ruffmann C, Parkkinen L. Gut feelings about alphasynuclein in gastrointestinal biopsies: Biomarker in the making Mov. Disord. 31(2), 193-202 (2016).
9. Lee JM, Derkinderen P, Kordower JH, et al. The search for a peripheral biopsy indicator of-synuclein pathology for Parkinson disease. JNEN 76 (1), 2-15 (2017).
10. Corbille AG, Letournel F, Kordower JH, et al. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol. Commun. 4, 35 (2016).
11. Beach TG, Corbillé A-G, Franck Letournel, et al. Multicenter assessment of immunohistochemical methods for pathological alpha-synuclein in sigmoid colon of autopsied Parkinson's disease and control subjects. J. Parkinsons Dis. 6(4), 761-770 (2016)
12. Donadio V, Incensi A, Leta V, et al. Skin nerve alphasynuclein deposits: A biomarker for idiopathic Parkinson disease. Neurology 82(15), 1362-1369 (2014).
13. Donadio V, Incensi A, Piccinini C, et al. Skin nerve misfolded alpha-synuclein in pure autonomic failure and Parkinson disease. Ann. Neurol. 79(2), 306-316 (2016).
14. Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease. Neurology 87(5), 505-512 (2016).
15. Navarro-Otano J, Casanova-Mollà J, Morales M, Valls-Solé J, Tolosa E. Cutaneous autonomic denervation in Parkinson's disease. J. Neural Transm. (Vienna) 122(8), 1149-1155 (2015).
16. Wang N, Gibbons CH, Lafo J, Freeman R.-synuclein in cutaneous autonomic nerves. Neurology 81(18), 1604-1610 (2013).
17. Doppler K, Ebert S, Uceyler N, et al. Cutaneous neuropathy in Parkinson's disease: A window into brain pathology. Acta Neuropathol. 128(1), 99-109 (2014).
18. Haga R, Sugimoto K, Nishijima H, et al. Clinical utility of skin biopsy in differentiating between Parkinson's disease and multiple system atrophy. Parkinsons Dis. 2015, 167038 (2015).
19. Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated alpha-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 138(Pt 8), 2310-2321 (2015).
20. Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J. Neuropathol. Exp. Neurol. 67(10), 945-953 (2008)
21. Miki Y, Tomiyama M, Ueno T, et al. Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. Neurosci. Lett. 469(3), 357-359 (2010).
22. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov. Disord. 29(8), 1010-1018 (2014).
23. Adler CH, Dugger BN, Hinni ML, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 82(10), 858-864 (2014).
24. Beach TG, Adler CH, Dugger BN, et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 72(2), 130-136 (2013).
25. Beach TG, Adler CH, Serrano G, et al. Prevalence of submandibular gland synucleinopathy in Parkinson's disease, dementia with Lewy bodies and other Lewy body disorders. J. Parkinsons Dis. 6(1), 153-163 (2016).
26. Adler CH, Dugger BN, Hentz JG, et al. Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings. Mov. Disord. 31(2), 250-256 (2016).
27. Vilas D, Iranzo A, Tolosa E, et al. Assessment of alphasynuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. Lancet Neurol. 15(7), 708-718 (2016)
28. Atik A, Stewart T, Zhang J. Alpha-synuclein as a biomarker for Parkinson's disease. Brain Pathol. 26(3), 410-418 (2016).
29. Mollenhauer B, Parnetti L, Rektorova I, et al. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. J. Neurochem. 139(Suppl. 1), 290-317 (2015).
30. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006).
31. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural Transm. (Vienna) 113(10), 1435-1439 (2006).
32. Li QX, Mok SS, Laughton KM, et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp. Neurol. 204(2), 583-588 (2007).
33. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J. Clin. Neurol. 7(4), 215-222 (2011).
34. Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva alphasynuclein and a high extinction coefficient protein: A novel approach in assessment biomarkers of Parkinson's disease. N. Am. J. Med. Sci. 6(12), 633-637 (2014).
35. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: Potential biomarkers for Parkinson's disease. Brain 134(Pt 7), e178 (2011).
36. Vivacqua G, Latorre A, Suppa A, et al. Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease. PLoS ONE 11(3), e0151156 (2016).
37. Klos KJ, Ahlskog JE, Josephs KA, et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66(7), 1100-1102 (2006).
38. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: Clinical comparison to a control cohort. Mov. Disord. 25(5), 642-646 (2010).
39. Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I. Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25(4), 304-314 (2005).
40. Bottner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol. Dis. 48(3), 474-480 (2012).
41. Muntane G, Ferrer I, Martinez-Vicente M.-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200, 106-119 (2012).
42. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 84(6), 609-616 (2015).
43. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766-1772 (2010).
44. Wang X, Yu S, Li F, Feng T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Neurosci. Lett. 599, 115-119 (2015).
45. Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RTQuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3(10), 812-818 (2016)
46. Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG. Anti-amyloid compounds inhibit alphasynuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J. Biol. Chem. 289(17), 11897-11905 (2014).
47. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 109(6), 583-588 (2005).
48. Takahashi M, Ikemura M, Oka T, et al. Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease. J. Neurol. Neurosurg. Psychiatry 86(9), 939-944 (2015).
49. Shishido T, Ikemura M, Obi T, et al. alpha-synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology 74(7), 608-610 (2010).
50. Systemic Synuclein Sampling Study Biologics Manual. www. michaeljfox. org/
51. Barbour R, Kling K, Anderson JP, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5(2), 55-59 (2008).
52. Systemic Synuclein Sampling Study. http://kits. iu. edu/s4/videos
53. BioFIND. www. michaeljfox. org/page. htmlbiofind-clinical-study
54. Parkinson's Disease Biomarkers Program. https://pdbp. ninds. nih. gov/
55. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: A dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33(6), 599-614 (2007).
56. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: The dual hit theory revisited. Ann. NY Acad. Sci. 1170, 615-622 (2009).
57. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117(6), 613-634 (2009).
58. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain J. Neuropathol. Exp. Neurol. 61(5), 413-426 (2002).
59. Orimo S, Uchihara T, Nakamura A, et al. Axonal alphasynuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131(Pt 3), 642-650 (2008).
60. The Michael J Fox Foundation for Parkinson's Research. www. michaeljfox. org/
61. The Michael J Fox Foundation for Parkinsons Research. www. michaeljfox. org/foundation/
62. Fagerqvist T, Lindstrom V, Nordstrom E, et al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alphasynuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 126(1), 131-144 (2013).
63. Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 138(Pt 6), 1642-1657 (2015).
64. Atarashi R, Sano K, Satoh K, Nishida N. Real-time quakinginduced conversion: A highly sensitive assay for prion detection. Prion 5(3), 150-153 (2011).
65. Kellie JF, Higgs RE, Ryder JW, et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci. Rep. 4, 5797 (2014).
66. Stuendl A, Kunadt M, Kruse N, et al. Induction of alphasynuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain 139(Pt 2), 481-494 (2016).